Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating a Urinary Catheter With Different Activation Times for the Wetting Solution, in Healthy Male Volunteers.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of written informed consent~* Healthy volunteer~* Male aged 18 years or over~Exclusion Criteria:~* Known or suspected, current impairment of and/or decreased urethral sensibility~* History of urethral morbidity~* History of urinary tract infection within three months, or ongoing symptomatic urinary tract infection~* Use of medications that may affect the urethra´s dryness (anti-cholinergic drugs or cortisone)~* Current drug, alcohol or other substance abuse~* Other significant disease or condition (e.g. benign prostate hypertrophy, other prostatic lesions), which may interfere with treatment and/or evaluation~* Allergy to antibiotics suspected poor compliance with the protocol during the complete study period

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- LoFric POBE Hydro-Kit II, 5 seconds and then LoFric POBE Hydro-Kit II, 24 hours (Type: EXPERIMENTAL): All subjects were first catheterizised with the reference catheter. After randomisation this group was first catheterizised with LoFric POBE Hydro-Kit II, activation time 5 seconds.~Then the next test catheter was used LoFric POBE Hydro-Kit II, activation time 24 hours.
- LoFric POBE Hydro-Kit II, 24 hours and then LoFric POBE Hydro-Kit II, 5 seconds (Type: EXPERIMENTAL): All subjects were first catheterizised with the reference catheter. After randomisation this group was first catheterizised with LoFric POBE Hydro-Kit II, activation time 24 hours.~Then the next test catheter was used LoFric POBE Hydro-Kit II, activation time 5 seconds.

Based on this trial design, predict the completion outcome and termination type (if applicable).